Citigroup’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Citigroup’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,854	Closed	-$177K	–	5932
2023 Q4	$177K	Sell	2,854 -22,053	-89%	-$548K	﹤0.01%	3961
2023 Q3	$553K	Buy	+24,907	New	+$523K	﹤0.01%	2982

Citigroup's RYZB Position: Q1 2024 in Review

Citigroup sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 2,854 shares — an estimated $177K sold.

Citigroup first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $553K in Q3 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Citigroup reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citigroup sold 2,854 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $177K.
Citigroup first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Citigroup's RayzeBio, Inc. Common Stock position peaked at $553K in Q3 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.